BeiGene announces first patient dosed in phase III trial of anti-TIGIT antibody, ociperlimab + tislelizumab in NSCLC.
This marks the initiation of the first Phase III clinical trial in the planned global pivotal program for ociperlimab.
AdvanTIG-302 Trial of Ociperlimab in Combination with Tislelizumab in NSCLC: AdvanTIG-302 is a randomized, double-blind, multicenter, global Phase III clinical trial (NCT04746924), expected to enroll approximately 605 treatment-naïve patients with locally advanced, unresectable, or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations in the United States, Australia and other countries and regions across the globe. Patients will be randomized to receive ociperlimab and tislelizumab combination treatment, pembrolizumab, or tislelizumab alone. The primary endpoints of the trial are progression-free survival (PFS) and overall survival (OS) in the intention-to-treat (ITT) population; secondary endpoints include safety and other efficacy endpoints.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins